Latest news with #Blueprint
Business Recorder
2 hours ago
- Business
- Business Recorder
Sanofi to buy US biopharma group Blueprint for over $9 billion
PARIS: France's Sanofi has agreed to buy U.S.-based Blueprint Medicines Corporation for over $9 billion to boost its position in rare immunology diseases, in what would be the biggest healthcare deal in Europe this year, according to LSEG data. Blueprint is a specialist in treatments for systemic mastocytosis, a rare immunological disorder. The acquisition 'represents a strategic step forward in our rare and immunology portfolios. It enhances our pipeline and accelerates our transformation into the world's leading immunology company,' said Sanofi CEO Paul Hudson. The deal would add to Sanofi's portfolio the rare immunology disease drug Ayvakit/Ayvakyt, approved in the U.S. and the EU, and a promising advanced and early-stage immunology pipeline. Blueprint's established presence among allergists, dermatologists, and immunologists is also expected to enhance Sanofi's growing immunology pipeline, the companies said. Ayvakit/Ayvakyt is the only approved medicine for advanced and indolent systemic mastocytosis, which is characterised by the accumulation and activation of aberrant mast cells in bone marrow, skin, the gastrointestinal tract, and other organs. Sanofi to invest at least $20 billion in the US through 2030 The acquisition would also bring elenestinib, a next-generation medicine for systemic mastocytosis, as well as BLU-808, a highly selective and potent oral wild-type KIT inhibitor that has the potential to treat a broad range of diseases in immunology. It is the latest in a series of deals struck by Sanofi. Last month, it announced the $470 million purchase of Vigil Neuroscience and in January 2024 it struck a $2.2 billion deal for U.S biotech firm Inhibrx. Sanofi's shares opened little changed. Besides $129.00 per share in cash, Blueprint shareholders would also receive one non-tradeable contingent value right (CVR) which would entitle the holder to receive two potential milestone payments of $2 and $4 per CVR for the achievement, respectively, of future development and regulatory milestones for BLU-808. The total equity value of the transaction, including potential CVR payments, would be approximately $9.5 billion on a fully diluted basis. Hudson said the deal complemented Sanofi's recent acquisitions of other early-stage medicines and added that it still retained a sizable capacity for further acquisitions.
Time of India
3 hours ago
- Business
- Time of India
Sanofi buys US biopharma group Blueprint in $9.1 billion deal
French pharma group Sanofi has agreed to buy US-based Blueprint Medicines Corporation , a biopharmaceutical company specializing in systemic mastocytosis, a rare immunological disease, the companies said on Monday. Under the terms of the acquisition, Sanofi will pay $129.00 per share in cash, representing an equity value of approximately $9.1 billion. The acquisition "represents a strategic step forward in our rare and immunology portfolios. It enhances our pipeline and accelerates our transformation into the world's leading immunology company," said Sanofi CEO Paul Hudson. The deal will add to Sanofi's portfolio the rare immunology disease drug Ayvakit/Ayvakyt (avapritinib), approved in the US and the EU, and a promising advanced and early-stage immunology pipeline . Blueprint's established presence among allergists, dermatologists, and immunologists is also expected to enhance Sanofi's growing immunology pipeline, the companies said. Live Events Ayvakit/Ayvakyt is the only approved medicine for advanced and indolent systemic mastocytosis, a rare immunology disease, which is characterized by the accumulation and activation of aberrant mast cells in bone marrow, skin, the gastrointestinal tract, and other organs. The acquisition will also bring elenestinib, a next-generation medicine for systemic mastocytosis, as well as BLU-808, a highly selective and potent oral wild-type KIT inhibitor that has the potential to treat a broad range of diseases in immunology. Besides $129.00 per share in cash at the closing of the deal, Blueprint shareholders will also receive one non-tradeable contingent value right (CVR) which will entitle the holder to receive two potential milestone payments of $2 and $4 per CVR for the achievement, respectively, of future development and regulatory milestones for BLU-808. The total equity value of the transaction, including potential CVR payments, represents approximately $9.5 billion on a fully diluted basis. Hudson said the deal complements recent acquisitions of other early-stage medicines that remain Sanofi's main field of interest and added that Sanofi still retains a sizeable capacity for further acquisitions.
CTV News
3 days ago
- Business
- CTV News
Alberta's D+ grade on housing report card is lowest among provinces
Alberta is ranked dead last in Canada in a new report evaluating home building progress. Alberta is ranked dead last in Canada in a new report evaluating home building progress. Alberta received the lowest grade among Canadian provinces on a report evaluating home building progress. The Report Card on More and Better Housing gave Alberta an overall score of D+ for 'failing to adopt better building codes, incentivize factory-built housing, and regulate construction in flood-prone areas.' 'This, in spite of smart reforms being implemented by municipal governments in Calgary and Edmonton,' the report reads. The report card was commissioned by the Task Force for Housing and Climate. The task force was formed in 2023 to provide practical and actionable advice to governments on housing. It created the Blueprint for More and Better Housing, offering 'a comprehensive set of more than 140 policy actions for adding 5.8 million homes by 2030 that are affordable, low carbon and resilient.' 'Provincial governments control the bulk of housing policy tools and must step up,' said Dr. Mike Moffatt, a task force member and author of the report card. 'Provinces often speak about the housing crisis, but many are not walking the talk. Without meaningful reform from all orders of government, we won't build the homes Canadians need.' The federal government earned the highest grade on the report card, with a B. The report says the federal government adopted key recommendations, including 'federal tax incentives for rental construction, leasing of federal land for housing, and incentivizing municipal zoning reforms, which are having a positive impact on housing supply.' The provincial and federal governments were evaluated based on five categories relative to the task force's blueprint: Legalize density; Implement better building codes; Invest in factory-built housing; Avoid high-risk areas; and Fill in market gaps. 'Alberta has done less to legalize family-friendly density than other provinces and is lagging on resiliency and energy efficiency,' the report reads. No province received a grade higher than a C+. Quebec, Prince Edward Island and British Columbia all scored a C+, while New Brunswick and Ontario got Cs. Saskatchewan, Nova Scotia, Newfoundland and Labrador and Manitoba all got a C-, while Alberta sat alone with a D+. 'Calgary and Edmonton have taken leadership and instituted several helpful reforms on issues ranging from zoning to approval processes. Work on adopting these provincewide. Institute hazard mapping reforms and ensure homes are not built in areas prone to floods and wildfires,' the report said. The group on the task force is bipartisan, with former Edmonton Mayor Don Iveson and former Conservative Cabinet Minister Lisa Raitt involved. Mark Carney was a member of the group before he became the leader of the Liberal party. Read the full report on the task force's website.
Time of India
3 days ago
- Business
- Time of India
Founders are going direct — but startup rivalry is nothing new
Founders are going direct — but startup rivalry is nothing new Sabotage is an age-old tactic Rivalry, rebranded Preempting, not just reacting Welcome to a new edition of Full Stack. This is the place where you'll find unfiltered commentary on all things keep the bouquets, brickbats and suggestions coming. You can reach me at and follow me on Elon Musk's X @samidhas Few days ago, Zepto cofounder Aadit Palicha took to LinkedIn to publicly accuse the CFO of a rival consumer internet firm of trying to sabotage Zepto's was detailed and direct— complete with claims of investor calls, doctored Excel sheets, and even bot-backed social media chatter to discredit the company which is in the middle of a fundraise and potential post was discussed across WhatsApp groups, founder and investor forums, and of course, in media saw it as a meltdown, others called it me, it underscored something deeper: the battle for capital among high-growth startups is as personal as it is financial — and increasingly, it's playing out in public. But let's be clear — founders trying to undercut rivals during a fundraise isn't new. It's just more visible investor whisper campaigns to selectively leaked numbers, this sort of interference has long been part of high-stakes corporate rivarly. What's changed is the simply chose to call it out — and to do so in real time, on a platform like LinkedIn, rather than waiting for backchannel damage to this week, The Wall Street Journal reported that Elon Musk had privately tried to influence the multibillion-dollar AI supercomputing project Stargate, spearheaded by Sam tweets. No memes. Just classic playbook tactics — this time at trillion-dollar you've been in this business long enough, you'll remember how Travis Kalanick's Uber practically wrote the ops manual for startup India, Flipkart vs Amazon vs Snapdeal, Ola vs Uber, Swiggy vs Zomato — every funding milestone came with a shadow narrative of investor blocks and strategic different in 2025 is the speed — and source — of counter-narratives. Founders are now their own comms heads. And platforms like LinkedIn and X are where narrative wars play post wasn't just about calling out one executive — it was about taking control of the story before someone else could shape a strategy we've seen in Silicon Valley too. When The New York Times was preparing a critical profile on Bryan Johnson, the biohacker behind Blueprint, he got ahead of it. He framed his anti-ageing regimen as 'scientific progress under scrutiny' rather than a vanity project. By the time the article dropped, his version had already made the this new media ecosystem, investors and journalists are no longer the sole gatekeepers. Founders today are managing perception as much as performance. That means going direct — before rivals or reporters let's not over-inflate every act of rivalry into a scandal though. If a rival startup is trying to talk down your deal or cast doubt on your metrics, it doesn't always require a public maturity of founders should reflect in knowing when to hit back — and when to move Elon Musk has made going direct fashionable but not everything he does needs to founders would do better to focus on building durable businesses — not personal comms wars. A strong narrative helps. But strong numbers close the Sharma is Editor - ETtech. She's been covering the tech and new-age digital economy for over a decade, and has had a ringside view of the industry and its people.
Time of India
5 days ago
- Health
- Time of India
Indian coder's 4 AM post goes viral, but biohacker Bryan Johnson calls the hustle culture ‘toxic'-- Here's why
credit: instagram/@bryanjohnson_ A social media post shared by Indian web developer Priyanshu Tiwari surfaced, igniting a global conversation about work culture and health. Priyanshu shared a photo of himself and his colleagues working in an office, coding till 4 am, captioned, 'It is 4 am, guys, but builders are building. What's your excuse?' This post instantly went viral, gaining praise for the team's dedication. American entrepreneur and venture capitalist Bryan Johnson, who is also an anti-aging advocate, responded with a cautionary note, saying that such work habits are 'terrible for health' and should not be seen as 'heroic.' He further went on to highlight the adverse effects of prolonged screen time and poor posture, including reduced brain oxygen, suppressed melatonin production, fragmented sleep patterns, and whatnot. The digital divide: Health versus hustle credit: X/@ Johnson's candid comments evoked both admiration and criticism. His supporters praised him for speaking out about what they perceive as a poisonous work environment that MNCs and high-tech firms have glamorized. A user said, "Bryan is spot on.". This kind of schedule is not sustainable.' However, detractors accused Johnson of being out of touch with the struggles of young professionals who may not have the luxury to prioritize culture over work and sleep deadlines. Another user on X commented, 'Easy to give this advice from your villa in Venice when you've already made millions,' pointing out the disparity in lived experiences To which Bryan responded calmly, 'Even small improvements in sleep posture and circadian rhythm can enhance performance and longevity. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Click Here - This Might Save You From Losing Money Expertinspector Click Here Undo It's not either-or.' Do we love the 'overworking' culture? A 2021 report by WHO indicated that prolonged working hours led to 745,000 deaths worldwide due to heart disease and stroke, especially. The study concludes that working 55 or more hours per week is associated with an estimated 35% higher risk of a stroke and a 17% higher risk of dying from ischemic heart disease, compared to working 35-40 hours a week. Further, the number of people working long hours is increasing and currently stands at 9% of the total population globally. This trend puts even more people at risk of work-related disability and early death. This exchange has highlighted a growing concern in the tech industry: the pressure to reach targets and work for longer hours and the romanticization of burnout. This glorification can come at a higher cost than expected. Bryan Johnson, a voice of biohacking Bryan Johnson is not a stranger to controversy. This 47-year-old millionaire has made headlines for investing hundreds of millions of dollars annually into his own body to reverse aging. His famous health program, Blueprint, follows a strict regimen of over 100 supplements, monitored sleep, and data-driven exercise. Does this mean more working hours for the upcoming generation? Priyanshu Tiwari's post was undoubtedly meant to inspire. In many ways, it reflects the dedication of a generation willing to push boundaries for success. But Johnson's critique introduces an essential counter-narrative: at what cost? As the world becomes more aware of mental and physical health, it becomes more and more imperative to counteract centuries-old myths of what productivity really means. A balanced schedule, proper rest, and ergonomically conscious work habits aren't luxuries; they're requirements for long-term performance. One step to a healthier you—join Times Health+ Yoga and feel the change
